Phase 3b trial shows long-acting injectable therapy outperforms daily oral regimens for patients with detectable HIV-1 and adherence challenges.

Phase 3 PROPEL 3 trial results show daily oral infigratinib significantly improved annualized height velocity and height Z-scores compared with placebo in children with achondroplasia.

Net decreases in prevalence seen across age groups, with largest relative reduction for young adults aged 18 to 29 years.

Combined tobacco and e-cigarette exposure linked to increase in activity-related symptoms, nighttime symptoms, albuterol use.

In national prospective study, 2.9% of those undergoing anesthesia reported receiving GLP-1 receptor agonists.